Q2 2024 EARNINGS SUPPLEMENT JULY 31, 2024 LEGAL DISCLAIMER This earnings supplement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future financial and operating results of the Company, estimates of future EBITDA, the timing and performance of new store openings, future reductions in cost of capital and leverage ratio, our ability to conduct future accretive acquisitions and our pipeline of new store locati ...

Vir Biotechnology Q2:24 Investor Conference Call August 1st 2024 © 2024 Vir Biotechnology, Inc. 1 Legal Disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the "Company" or "Vir"); the Company's strategy and plans; capital allocation; financial and operating results and it ...

财务数据 - Q2 2024财务摘要显示，Fire Safety部门的营收同比增长85%至53,140,000美元[10] - 调整后的EBITDA从Q2 '23的16,532,000美元增长至Q2 '24的55,639,000美元，同比增长237%[11] - Specialty Products部门的营收同比增长25%，调整后的EBITDA同比增长108%[11] - 公司整体营收从Q2 '23的76,137,000美元增长至Q2 '24的127,276,000美元，同比增长67%[11] - 公司整体调整后的EBITDA从Q2 '23的24,106,000美元增长至Q2 '24的77,044,000美元，同比增长220%[11] - 公司整体调整后的EBITDA利润率从Q2 '23的28%增长至Q2 '24的51%[11] 长期展望 - 长期假设包括年度利息支出约4000万美元，税率约26%，资本支出约1000-1500万美元[12] - 公司长期增长记录显示，2010年至2023年，营收年复合增长率为9%，调整后的EBITDA年复合增长率为11%[20] 股份信息 - 公司拥有145.3万股基本股份，固定年度顾问股份为9.4万股，变动年度顾问股份为0.0万股，加权平均稀释股份为154.7万股[16]

Corporate Presentation August 2024 Confidential and Proprietary Forward Looking Statements Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations and projections regarding our future operating results and financial performance, anticipated cost or expense reductions, plans with respect to commercializing our product and product candidates, our translational research program, expectation ...

Q2 2024 Earnings Slides August 1, 2024 Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding guidance, our future results of operations or financial condition, future stock repurchase programs or stock dividends, business strategy and plans, user growth and e ...

T C E N E R G Y 2 0 2 3 I N V E S T O R D A Y T C E N E R G Y S E C O N D Q U A R T E R 2 0 2 4 C O N F E R E N C E C A L L Second quarter 2024 conference call August 1, 2024 T C E N E R G Y 2 0 2 3 I N V E S T O R D A Y T C E N E R G Y S E C O N D Q U A R T E R 2 0 2 4 C O N F E R E N C E C A L L Call participants François Poirier – President and Chief Executive Officer Sean O'Donnell – Executive Vice-President and Chief Financial Officer Stanley G. Chapman, III – Executive Vice-President and Chief Operati ...

业绩总结 - 第二季度2024年新资产收益率为10.5%[8] - 第二季度调整后每股收益为0.63美元[9] - 利息支出从2024年第一季度的5.7%下降至第二季度的5.6%[81] - 公司长期业务模型的调整后每股收益年复合增长率为8-10%[142] - 公司预计年度调整后每股盈利将以8%至10%的复合年增长率增长[164] 用户数据 - 公司管理资产每年避免的排放量为800万吨二氧化碳[16] - 管理资产自2020年以来增长超过80%[48] - 公司拥有55%的自用电力设施[106] 未来展望 - 美国未来10年预计将新增约1000吉瓦的新可再生能源容量[20] - 公司在2024年6月30日认为某些投资不可收回，将其排除在调整后的收益之外[181] 新产品和新技术研发 - CarbonCount® 是评估实物资产效率的专有评分工具，用于确定每美元投资资本避免的年度二氧化碳当量排放量[93] - WaterCountTM 是评估美国项目投资的评分工具，用于估计每1000美元投资的预期节水量减少[94] 市场扩张和并购 - 公司债务与股本比率为1.8倍，符合1.5-2.0的目标[88] - 公司在2024年6月30日，调整后的现金流量为287,129美元[178]

SECOND QUARTER 2024 FINANCIAL RESULTS AUGUST 1, 2024 ©2024 Vertex Pharmaceuticals Incorporated AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2024 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR STATEME ...

Q2 2024 Company Update August 1, 2024 DISCLAIMER Forward Looking Statements This presentation contains forward looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the Company's results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: infor ...

Investor Presentation 2024 Disclaimers Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "explore," "intend," "long-term model," "may," "might" "outlook," "plan," "potential," "predic ...